Idexx Laboratories Stock News

IDEXX Laboratories <> is trading higher for the fifth straight session after the veterinary services company exceeded expectations with its Q4 2021 results despite issuing

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q4 2021 Results - Earnings Call Transcript

IDEXX Laboratories has directly benefitted from the COVID-19 pandemic as diagnostic testing of animals has increased. Share prices and earnings per share have been increasing consistently over the las

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Idexx (IDXX) delivered earnings and revenue surprises of 13.17% and 2.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to announce Q4 earnings results on Wednesday, Feb. 2, before market open.

Following the partnership between IDEXX (IDXX) and PetDx , the test is likely to be available later in January to all veterinary customers of IDXX in the United States and Canada.

Idexx Laboratories (IDXX) closed at $661.32 in the latest trading session, marking a +0.86% move from the prior day.

IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.

Idexx Laboratories (IDXX) closed at $645.02 in the latest trading session, marking a +0.78% move from the prior day.

Cortland Associates Inc. MO lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,810 shares of the companys stock after buying an additional 36 shares during the quarter. IDEXX Laboratories comprises 1.6% of []

Nordea Investment Management AB grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 93.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,030 shares of the companys stock after purchasing an additional 43,047 shares during the period. Nordea Investment Management AB owned about [] The post Nordea Investment Management AB Has $56.61 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) appeared first on ETF Daily News .

Mitchell Capital Management Co. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the third quarter, Holdings Channel reports. The fund owned 9,521 shares of the companys stock after selling 171 shares during the period. IDEXX Laboratories makes up 1.3% of Mitchell Capital Management Co.s holdings, making the stock its 15th largest holding. []

B. Metzler seel. Sohn & Co. Holding AG lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,300 shares of the companys stock after selling 97 shares during the period. []